News Breaks |
|
|
| March 19, 2013 |
| 05:55 EDT |  | LLY, LLY, LLY, DNA, DNA, DNA, BMY, BMY, BMY, PFE, PFE, PFE, RHHBY, RHHBY, RHHBY, BIIB, BIIB, BIIB, JAZZ, JAZZ, JAZZ, SNY, SNY, SNY, GILD, GILD, GILD, CORT, CORT, CORT, HZNP, HZNP, HZNP | Drug Information Association to host a forum
Medical & Scientific Communications 2013 Annual Forum is being held in Chandler, Arizona on March 19-21. |
|
|
News For LLY;CORT;GILD;SNY;JAZZ;BIIB;RHHBY;PFE;BMY;DNA;HZNP From The Last 14 Days Check below for free stories on LLY;CORT;GILD;SNY;JAZZ;BIIB;RHHBY;PFE;BMY;DNA;HZNP the last two weeks. |
|
|
| May 17, 2013 |
| 13:21 EDT |  | BMY | Options with increasing implied volatility: CPRT BMY GDI HNZ
 Subscribe for More Information |
|
| 08:03 EDT |  | SNY | Sanofi reports positive topline results from pivotal Phase III Jakarta study
Subscribe for More Information |
|
| 05:18 EDT | | SNY | Sanofi says JAK2 inhibitor for myelofibrosis met primary endpoint
Subscribe for More Information |
|
| May 16, 2013 |
| 16:32 EDT | | BMY | Bristol-Myers announces intention to voluntarily delist preferred stock
Subscribe for More Information |
|
| 13:20 EDT |  | BMY | Follow-up: Bristol-Myers upgraded to Outperform from Market Perform at Leerink
Leerink upgraded Bristol-Myers citing the company's multi-billion dollar immuno-oncology prospects. The firm says there were additional responses reported in the press briefing with combination nivolumab and Yervoy. Leerink has a $51 price target for shares. |
|
| 13:14 EDT | | BMY | Bristol-Myers upgraded to Outperform from Market Perform at Leerink
Subscribe for More Information |
|
| 11:50 EDT | | GILD | Celgene, Gilead lower after new data published at ASCO
Subscribe for More Information |
|
| 08:55 EDT | | BMY, PFE, LLY | BofA/Merrill's pharmaceuticals analysts hold analyst/industry conference call
Subscribe for More Information |
|
| 08:38 EDT |  | BMY | Bristol-Myers shares likely to give back recent gains, says Leerink
Leerink expects shares of Bristol-Myers to give back recent gains after ASCO published abstracts last night. The firm found the abstracts as in-line with, but not above, its expectations for nivolumab alone or immuno-oncology combination therapy and keeps a Market Perform rating on Bristol-Myers. |
|
| 07:29 EDT | | BIIB | Leerink to host a bus tour
Boston Biopharma Bus Tour travels throughout Boston on May 16-17. |
| |
| 05:52 EDT | | BMY | Stocks with implied volatility movement; BMY SLV
Subscribe for More Information |
|
| May 15, 2013 |
| 18:32 EDT | | GILD | Gilead announces response data from Phase 2 study of Idelalisib
Subscribe for More Information |
|
| 15:59 EDT |  | RHHBY | Roche exploring sale of blood glucose meters unit, Reuters says
Subscribe for More Information |
|
| 15:16 EDT | | SNY | Sanofi systemic sclerosis treatment designated for orphan drug status
Subscribe for More Information |
|
| 12:13 EDT | | RHHBY | Roche management to meet with Jefferies
Meeting to be held in London on May 17 hosted by Jefferies. |
|
| 11:38 EDT | | RHHBY | Roche says FDA approves Tarceva tablets for specific lung cancer situation
Subscribe for More Information |
|
| 11:28 EDT | | BMY | Options with increasing implied volatility: BMY AGNC EBIX IAU
Subscribe for More Information |
|
| 09:43 EDT | | BMY | Active equity option families trading on open
Subscribe for More Information |
|
| 05:39 EDT | | SNY | Sanofi, Regeneron announce patient enrollment in two Phase 3 trials
Subscribe for More Information |
|
| May 14, 2013 |
| 16:55 EDT | | RHHBY | FDA approves Roche's cobas EGFR mutation test with Tarceva
Subscribe for More Information |
| |
|
|
|
|
